Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Structure-activity relationship analysis of peptides targeting the EphA2 receptor.

Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB.

Biochemistry. 2010 Aug 10;49(31):6687-95. doi: 10.1021/bi1006223.

2.

Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.

Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, Roth GP, Pasquale EB.

J Biol Chem. 2008 Oct 24;283(43):29461-72. doi: 10.1074/jbc.M804103200. Epub 2008 Aug 26.

3.

An ephrin mimetic peptide that selectively targets the EphA2 receptor.

Koolpe M, Dail M, Pasquale EB.

J Biol Chem. 2002 Dec 6;277(49):46974-9. Epub 2002 Sep 25.

4.

Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.

Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.

J Biol Chem. 2013 Jun 21;288(25):18448-57. doi: 10.1074/jbc.M113.464008. Epub 2013 May 9.

5.

Homing peptide-conjugated gold nanorods: the effect of amino acid sequence display on nanorod uptake and cellular proliferation.

Alkilany AM, Boulos SP, Lohse SE, Thompson LB, Murphy CJ.

Bioconjug Chem. 2014 Jun 18;25(6):1162-71. doi: 10.1021/bc500174b. Epub 2014 Jun 3.

PMID:
24892190
6.

Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.

Tognolini M, Incerti M, Hassan-Mohamed I, Giorgio C, Russo S, Bruni R, Lelli B, Bracci L, Noberini R, Pasquale EB, Barocelli E, Vicini P, Mor M, Lodola A.

ChemMedChem. 2012 Jun;7(6):1071-83. doi: 10.1002/cmdc.201200102. Epub 2012 Apr 23.

7.

Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.

Guo Z, He B, Yuan L, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q.

Int J Pharm. 2015 Sep 30;493(1-2):380-9. doi: 10.1016/j.ijpharm.2015.05.051. Epub 2015 May 21.

PMID:
26004003
8.

Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.

Yang NY, Fernandez C, Richter M, Xiao Z, Valencia F, Tice DA, Pasquale EB.

Cell Signal. 2011 Jan;23(1):201-12. doi: 10.1016/j.cellsig.2010.09.004. Epub 2010 Sep 15.

9.

(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.

Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, Wen Q, An R.

Nucl Med Biol. 2014 Jul;41(6):450-6. doi: 10.1016/j.nucmedbio.2014.03.020. Epub 2014 Mar 29.

PMID:
24768147
10.

A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Singh DR, Pasquale EB, Hristova K.

Biochim Biophys Acta. 2016 Sep;1860(9):1922-8. doi: 10.1016/j.bbagen.2016.06.004. Epub 2016 Jun 6.

11.

Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.

Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A, Tognolini M.

PLoS One. 2011 Mar 30;6(3):e18128. doi: 10.1371/journal.pone.0018128.

12.

Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.

Tognolini M, Incerti M, Pala D, Russo S, Castelli R, Hassan-Mohamed I, Giorgio C, Lodola A.

ChemMedChem. 2014 Jan;9(1):67-72. doi: 10.1002/cmdc.201300305. Epub 2013 Sep 20.

PMID:
24115725
13.

Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.

Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M, Lodola A.

J Chem Inf Model. 2014 Oct 27;54(10):2621-6. doi: 10.1021/ci5004619. Epub 2014 Oct 7.

PMID:
25289483
14.

Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.

Patel K, Doddapaneni R, Sekar V, Chowdhury N, Singh M.

Mol Pharm. 2016 Jun 6;13(6):2049-58. doi: 10.1021/acs.molpharmaceut.6b00187. Epub 2016 Apr 26.

15.

UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M.

Br J Pharmacol. 2014 Dec;171(23):5195-208. doi: 10.1111/bph.12669. Epub 2014 Aug 28.

16.

The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.

Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB.

Oncogene. 2000 Dec 7;19(52):6043-52.

17.

Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.

Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J.

J Biol Chem. 2008 Jun 6;283(23):16017-26. doi: 10.1074/jbc.M709934200. Epub 2008 Apr 3.

18.

Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.

Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, Giorgio C, De Franco F, Gioiello A, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A.

Molecules. 2013 Oct 21;18(10):13043-60. doi: 10.3390/molecules181013043.

19.

Receptor-binding domain of ephrin-A1: production in bacterial expression system and activity.

Nekrasova OV, Sharonov GV, Tikhonov RV, Kolosov PM, Astapova MV, Yakimov SA, Tagvey AI, Korchagina AA, Bocharova OV, Wulfson AN, Feofanov AV, Kirpichnikov MP.

Biochemistry (Mosc). 2012 Dec;77(12):1387-94. doi: 10.1134/S0006297912120073.

PMID:
23244735
20.

Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.

Koshikawa N, Hoshino D, Taniguchi H, Minegishi T, Tomari T, Nam SO, Aoki M, Sueta T, Nakagawa T, Miyamoto S, Nabeshima K, Weaver AM, Seiki M.

Cancer Res. 2015 Aug 15;75(16):3327-39. doi: 10.1158/0008-5472.CAN-14-2798. Epub 2015 Jun 30.

Supplemental Content

Support Center